Baby skincare brand
~$2,900 per year
Product liability
- Introduced under AICIS registration, dermatologically tested
- Australian formulation, overseas manufacture
- All standard markets declined
- Placed to enable retail launch
Peptide, Cosmetic & Skincare Insurance
Product classification and the claims made in advertising matter as much as the ingredient list. Appetite is selective, so the submission has to be precise.
Specialist
Market access
Hard-to-place
Our focus
Australia
National broking
Recognition
Emerging products
The Tank take
Peptide, cosmetic and skincare risks can be insurable, but appetite is selective and can change quickly. The submission needs the product and ingredient list, intended use, claims, regulatory pathway, quality evidence, suppliers, testing, labels, complaints and countries assembled before appetite is tested.
A product marketed as cosmetic can move toward therapeutic-goods territory when its intended use or advertising claims change. The business should distinguish its TGA, AICIS and other obligations product by product rather than relying on a broad category label.
The classification trap
Your advertising can reclassify your product
The regulatory and underwriting classification of a skincare or peptide product follows its intended use and the claims made about it, not just the formulation. A moisturiser is a cosmetic; the same formulation marketed as treating a skin condition starts to look like a therapeutic good, with different obligations and a different insurance conversation.
Underwriters read labels, websites, social media and practitioner materials against the formal regulatory position. Inconsistency between them is one of the fastest ways to lose an otherwise placeable risk.
The product story has to stay consistent across formulation, label, website, customer pathway and regulatory position - and it has to stay consistent over time, because a claim made in one campaign can be quoted back at claim time.
Market backdrop, as at August 2026: peptide risk appetite has narrowed. On the submissions we've taken to market recently, insurers and underwriters are hesitating even where the pack is complete. That reflects the current regulatory and market backdrop around peptides rather than any single risk, and it's a dated observation that can shift as appetite moves.
Underwriting focus
The four things insurers probe on these products
Claims about treating, preventing or modifying health conditions can alter regulatory and underwriting classification. 'Cosmetic' is a claims discipline, not just a category.
Certificates of analysis, supplier quality and ingredient legality support the submission. For peptides specifically, underwriters commonly want product-by-product status, pathway and manufacturing controls rather than a category-level answer.
GMP evidence, batch release, stability data and temperature controls matter wherever product integrity can deteriorate between manufacture and customer.
Prescription, practitioner, wholesale and direct-to-consumer channels create different responsibilities and different severity. D2C sale of active products is priced accordingly.
Speak to a specialist
Complex science deserves a precise submission
Tell us what you advise on, build, test, supply or operate. We take the risk to insurers with genuine life sciences appetite and explain the terms before you decide.
Placement evidence
Consumer product placements from Tank's book
Two anonymised consumer-product placements that show what specialist markets can do when the submission is complete.
Children's products importer
~$1,200 per year
$20M public + products
- Children's mealtime goods, silicone and stainless steel
- Compliant with Australian mandatory safety standards
- $20M required by retailers before listing
- Placed after the main market panel declined
Historical premiums from real Tank placements, rounded up and anonymised. They are evidence, not quotes - a different profile, or the same profile a year later, can price differently.
The submission pack
What to assemble before testing appetite
- 01
Every product, ingredient, concentration and intended use
- 02
The claims appearing on labels, websites, social media and practitioner material
- 03
The TGA, AICIS or other pathway applying to each product
- 04
Who manufactures, releases and tests each batch
- 05
Cold chain, complaints, adverse-event and recall controls
- 06
Supplier indemnities, insurance and rights of recourse
Peptide risks can face restricted appetite even with detailed controls. Early market testing beats late surprises.
Primary guidance
Check the current Australian guidance
Regulatory obligations sit outside your insurance policy. These official sources are the starting point.
Regulator AICIS - Cosmetics and personal-care products Primary guidance on industrial chemicals used in cosmetics and personal-care products. Regulator ACCC Product Safety - Notify a recall Official Australian guidance for telling the ACCC about a voluntary product recall.
External government and industry sources. Tank Insurance is not responsible for their content; confirm current requirements with the relevant body.
Keep reading
Related life sciences guides
Life sciences insurance hub
Explore cover by business activity
Biomedical Engineers & Consultants PI, products, repair, clinical boundaries and contracts for specialist scientific consultants. Medical Devices & Products Insurance architecture for device designers, manufacturers, importers, distributors and pre-revenue ventures. Clinical Research & Trials PI, clinical trials, medical liability and cyber for consultants, CROs, sponsors and research organisations. Biotechnology & Laboratories Cover for scientific consulting, R&D, laboratories, samples, products, trials and research data. Digital Health & AI Technology PI, cyber, medical boundaries and software-device questions for health platforms and AI tools.
Common questions
Questions about Peptides & Cosmetics
Potentially, but market appetite can be narrow and change quickly. Detailed product, regulatory, quality and supply-chain evidence is essential, and underwriters commonly assess product by product rather than by category.
No. Ingredients, intended use, claims, contamination potential, users, countries and manufacturing controls all matter. A cosmetic sold to infants can be priced above a simple therapeutic product.
Supplier or laboratory evidence about a material or batch. Underwriters use it alongside broader quality and testing controls to assess ingredient and manufacturing risk.
They show how customers are invited to use and rely on the product, and they can differ from the formal regulatory description. Underwriters and regulators both read them.
General information only. This page does not take account of your objectives, financial situation or needs and is not legal advice. Cover depends on the insurer, policy wording, limits, excesses, exclusions and information disclosed. Read the relevant policy documents and obtain professional advice before deciding.
Put your life sciences risk in front of the right markets
Tell us what you research, build, test, supply or operate, plus any overseas exposure. We will explain the available terms and exclusions before you decide.